ClinicalTrials.gg

Program

finerenone

Also written as “BAY94-8862”, “Finerenone (BAY94-8862)” and “Finerenone (Kerendia, BAY94-8862)”.

Its studies are mostly in Renal Insufficiency, Chronic · Heart Failure · Diabetic Nephropathies · Ventricular Dysfunction, Left · Diabetes Mellitus, Type 2, led by Bayer.

Furthest: phase 4, since Jan 20, 202325 company-led studies, 4 open or runningNext primary completion: Apr 10, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer254 open or runningphase 4since Jan 20, 2023Apr 29, 2011Apr 10, 2027phase 3 · NCT05196035

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since Apr 29, 2011.

  1. Sep 2, 20152 phase 3 studiesNCT02545049, NCT02540993
  2. Nov 3, 20162 phase 1 studies in PharmacokineticsNCT02956109, NCT02957396
  3. Jun 15, 2020Phase 3 study in Heart FailureNCT04435626 · 6,016 enrolled · United States, Argentina, Australia and more
  4. Feb 26, 2021No phase study in Diabetic RetinopathyNCT04795726 · 70 enrolled · Bulgaria, United Kingdom
  5. May 6, 20212 phase 1 studiesNCT04881994, NCT04908436
  6. Jul 20, 2021Phase 2 study in Renal Insufficiency, ChronicNCT05013008 · 951 enrolled · United States, Australia, Austria and more
  7. Sep 12, 2021Phase 3 study in Non-diabetic Chronic Kidney DiseaseNCT05047263 · 1,584 enrolled · United States, Argentina, Australia and more
  8. Jan 7, 2022Phase 3 study in Renal Insufficiency, ChronicNCT05196035 · 219 enrolled · United States, Argentina, Australia and more
  9. Feb 4, 2022Phase 2 study in Diabetes Mellitus, Type 2NCT05254002 · 1,664 enrolled · United States, Belgium, Canada and more
  10. Jul 11, 2022Phase 3 study in Renal Insufficiency, ChronicNCT05457283 · 100 planned · United States, Argentina, Australia and more
  11. Jan 20, 2023Phase 4 study in Renal Insufficiency, ChronicNCT05705271 · 200 enrolled · India
  12. Jun 5, 2023Phase 3 study in Renal Insufficiency, ChronicNCT05901831 · 242 enrolled · United States, Canada, China and more
  13. Aug 6, 2025Phase 1 study in Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per CentNCT07116512 · 60 enrolled · Germany
  14. Sep 8, 20252 phase 3 studies in Ventricular Dysfunction, LeftNCT07188805, NCT07192952

Ahead

  1. Apr 10, 2027Primary completion: phase 3 study in Renal Insufficiency, ChronicNCT05196035
  2. Aug 7, 2028Primary completion: phase 3 study in Renal Insufficiency, ChronicNCT05457283
  3. Nov 30, 2029Primary completion: phase 3 study in Ventricular Dysfunction, LeftNCT07188805
  4. Dec 30, 2030Primary completion: phase 3 study in Ventricular Dysfunction, LeftNCT07192952

TargetBeta

NR3C2 →read by rule
“Mineralocorticoid receptor antagonist”ChEMBL 37, by rule

Other programs on NR3C2

ProgramCompanyFurthest phaseStudies
drospirenoneruleestetraphase 420
vamorolonerulereveragen-biopharma-incphase 411
Spironolactonerulecmp-development-llcphase 48
balcinrenoneruleAstraZenecaphase 315
HRS-1780Jiangsu HengRui Medicinephase 37

Studies

All 25 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07192952Ventricular Dysfunction, Left · United States, Argentina, Austria and more3RecruitingDec 30, 2030117
NCT07188805Ventricular Dysfunction, Left · United States, Argentina, Austria and more3RecruitingNov 30, 2029111
NCT07116512Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent · Germany1CompletedJul 28, 202360
NCT05901831Renal Insufficiency, Chronic · United States, Canada, China and more3CompletedAug 20, 2025242
NCT05705271Renal Insufficiency, Chronic · India4CompletedJul 3, 2025200
NCT05457283Renal Insufficiency, Chronic · United States, Argentina, Australia and more3RecruitingAug 7, 2028100
NCT05254002Diabetes Mellitus, Type 2 · United States, Belgium, Canada and more2CompletedMar 14, 20251,664
NCT05196035Renal Insufficiency, Chronic · United States, Argentina, Australia and more3Active, not recruitingApr 10, 2027219
NCT05047263Non-diabetic Chronic Kidney Disease · United States, Argentina, Australia and more3CompletedDec 31, 20251,584
NCT05013008Renal Insufficiency, Chronic · United States, Australia, Austria and more2CompletedDec 31, 2021951
NCT04908436Renal Insufficiency, Chronic · Germany1CompletedMay 5, 201133
NCT04881994Diabetic Nephropathies · Germany1CompletedSep 16, 201427
NCT04795726Diabetic Retinopathy · Bulgaria, United Kingdom–CompletedJun 30, 202170
NCT04435626Heart Failure · United States, Argentina, Australia and more3CompletedMay 15, 20246,016
NCT02957396Pharmacokinetics · Germany1CompletedJan 13, 201716
NCT02956109Pharmacokinetics · Germany1CompletedDec 22, 201616
NCT02545049Diabetic Nephropathies · United States, Argentina, Australia and more3CompletedFeb 2, 20217,352
NCT02540993Renal Insufficiency, Chronic · United States, Argentina, Australia and more3CompletedApr 14, 20205,734
NCT01968668Diabetic Nephropathies · Japan2CompletedOct 9, 201496
NCT01955694Heart Failure · Japan2CompletedJan 23, 201572
NCT01874431Diabetic Nephropathies · United States, Australia, Austria and more2CompletedJul 9, 2014823
NCT01807221Heart Failure · United States, Australia, Austria and more2CompletedNov 11, 20141,066
NCT01687920Heart Failure · Germany1CompletedNov 28, 201225
NCT01473108Clinical Pharmacology · Germany1CompletedNov 30, 201067
NCT01345656Heart Failure · Austria, Belgium, Czechia and more2CompletedMay 30, 2012457

How it is read

Names in the registry

  • “BAY94-8862”, 10 entries
  • “Finerenone (BAY94-8862)”, 9 entries
  • “Finerenone (Kerendia, BAY94-8862)”, 6 entries
  • “BAY 94-8862”, 2 entries
  • “Finerenone”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.